This is the most beneficial and best investment potential drug have heard of in 21st century, NVG-291 by NervGen. The independent peer-reviewed study showed improved memory as well as motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke onset There is currently no FDA-approved drug for the repair of damage from a stroke NVG-291, currently in a Phase 1 clinical trial in healthy human subjects, could provide a completely new treatment paradigm for stroke patients On the Maze test it showed repair of 65% of the damage from the strokes even though used 7 days after the stroke. Here is chart of that in study:
VANCOUVER, British Columbia--(BUSINESS WIRE)-- NervGen Pharma Corp.(NGENF), , is pleased to announce the University of Cincinnati and Case Western Reserve University (CWRU) have published a pioneering preclinical study in the peer-reviewed scientific journal Cell Reports demonstrating that NervGen’s proprietary drug, NVG-291-R, promotes nervous system repair and significant functional recovery in a mouse model of severe ischemic stroke, even when treatment was initiated up to 7 days after onset. Currently there are no United States Food and Drug Administration (FDA) approved drugs that repair damage from a stroke. NervGen holds the exclusive worldwide rights to NVG-291, which is currently in a Phase 1 clinical trial in healthy human subjects and is preparing to initiate Phase 1b/2 clinical trials for the repair of nervous system damage from spinal cord injury, Alzheimer’s disease and multiple sclerosis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220727006174/en/
“We are very excited about the data showing significant improvement in motor function, sensory function, spatial learning, and memory, even when treatment was initiated as late as 7 days after stroke onset,” stated the senior author of the paper, Dr. Agnes (Yu) Luo, Associate Professor, Department of Molecular Genetics and Biochemistry at the University of Cincinnati. “If these results translate to the clinic, NVG-291 would be a substantial breakthrough in the treatment of stroke patients for multiple reasons because the only current FDA-approved drug for treatment of stroke does not repair damage and must be administered within 4.5 hours of stroke onset.” Dr. Luo continued, “Most therapies being researched today primarily focus on reducing the early damage from stroke. However, we have shown that treatment with NVG-291-R not only results in neuroprotection to reduce neuronal death but also robust neuroreparative effects.
Here is the full study: https://www.cell.com/cell-reports/fulltext/S2211-1247(22)00946-9 The market cap is only $100 million, so as BioPub has said this stock can 100 bag. Phase 2 FDA study starts in Q4, that is tests on humans for effectiveness. It is already in Phase 1 for safety on humans and has done well so far. The stock is unknown but with 29% gain yesterday may be getting discovered. Here is an article on the other studies, it includes videos of paralyzed rats regaining the ability to walk in 21 days. Here is an article on NervGen that covers all the diseases it has studies showing improvement on. https://ceo.ca/@geodan/nervgen-regenerates-neurons-what-is-a-drug-that-reverses-paralysis-ms-stroke-and-alzheimers-worth NervGen Regenerates Neurons, What Is A Drug That Reverses Paralysis, MS, Stroke And Alzheimer's Worth?
Market Data 
Markets 
AI
